Kidney Cancer Coverage from Every Angle

David A. Braun, MD, PhD, on Immunogenomics and Immunotherapy in Renal Cell Carcinoma

Posted: Monday, January 25, 2021

David A. Braun, MD, PhD, of Dana-Farber Cancer Institute, discusses current theories about why people do or do not respond to therapies, where the gaps in the field are, and how researchers can improve treatment for patients with kidney cancer.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.